• Contact
Saturday, June 28, 2025
Register
Login
European Press
Advertisement
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

Cognixion, Pupil Labs partner on eye-tracking interface

4 June 2025
in Health
Reading Time: 2 mins read
A A
Cognixion, Pupil Labs partner on eye-tracking interface
ShareShareShareShareShare


Cognixion, a developer of noninvasive brain-computer interface technology, and Pupil Labs, a company involved in eye-tracking tech, entered into a strategic partnership to develop an interface that measures visual attention and neural signals.
The aim is for Pupil Labs’ eye-tracking software to connect with Cognixion’s Axon-R SDK interface, which will allow for smooth data collection across platforms.
“High-precision eye tracking and advanced BCI [brain-computer interface] electroencephalogram capabilities will give clinical researchers powerful new tools for neuroscience, human-computer interaction and assistive technology research,” the companies said in a joint statement. 
The two technologies are expected to offer a higher level of data confidence and a platform that can adjust to the needs of patients, particularly those with diseases, such as amyotrophic lateral sclerosis (ALS), where progression may affect eye gaze ability.
According to Cognixion, the integrated tool will enable researchers to prototype and deploy studies that concurrently measure eye movements and brain activity, leveraging research-grade sensors for both modalities without intricate technical integration. 
It will also provide access to synchronized data streams via a unified developer interface, allowing the development of applications that respond to visual attention and neural signals.
Technical teams from the companies have started the integration process, and the first releases are expected within six months. 
“We’re building an ecosystem around the Cognixion platform that accelerates innovation for clinical researchers, while our noninvasive technology puts us in a position to expand our market share significantly,” Andreas Forsland, CEO of Cognixion, told MobiHealthNews.
“Continuing the integration of Cognixion’s Axon-R platform with new technologies is a key component of our growth. As we continue to forge new collaborations, our technology becomes exponentially more powerful when integrated with complementary solutions from industry leaders.”
THE LARGER TREND
In May, Cognixion announced that Blackrock Neurotech, a company that makes implantable BCIs, will provide Cognixion’s Axon-R wearable neural interface platform to research institutions via its distribution network.
Blackrock Neurotech will act as an unrestricted distributor of Cognixion’s Axon-R. This noninvasive wearable device enables the precise measurement and modulation of brain activity through visual stimuli, biofeedback and neurofeedback.
Other companies involved in the brain-neural interface space include Neuralink, which in May implanted its brain-computer interface into Brad Smith, an individual who has ALS and is completely nonverbal; the device allows Smith to communicate using Telepathy.
Smith released a video on X about his experience with Neuralink and how it works. The video is narrated using an AI-generated replica of Smith’s voice cloned from past recordings, and Smith uses the BCI to control the mouse on his MacBook Pro to perform the narration. 
In March, Neuralink filed applications with the U.S. Patent and Trademark Office (USPTO) to trademark the terms “Telepathy,” “Blindsight” and “Telekinesis.”  
The applications pertain to Neuralink’s first product, Telepathy, a brain-computer interface that aimed to enable users to control devices with their thoughts; Blindsight, an implant that aims to restore vision in individuals who are blind; and Telekinesis, a term Elon Musk, the company’s founder has used interchangeably with Telepathy relating to controlling devices using one’s mind.

Credit: Source link

Related Posts:

  • Cognixion, Pupil Labs partner on eye-tracking interface
    Cognixion, Pupil Labs partner on eye-tracking interface
  • Cognixion, Blackrock Neurotech partner on brain-computer interface technology
    Cognixion, Blackrock Neurotech partner on…
  • Phantom Neuro secures $19M to advance human-machine technology
    Phantom Neuro secures $19M to advance human-machine…
  • Synchron will enable thought control of Apple devices with brain implant
    Synchron will enable thought control of Apple…
ShareTweetSendPinShare
Previous Post

Japan’s ‘Baba Vanga’ warns of 2025 event that could lead to devastation

Next Post

CVS Health commits $20B to health-tech initiatives

Next Post
CVS Health commits B to health-tech initiatives

CVS Health commits $20B to health-tech initiatives

Recommended

Trump delays 50% tariffs on the EU to 9 July

Trump delays 50% tariffs on the EU to 9 July

30 May 2025
UK Export Finance unveils new tools to boost SME global trade

UK Export Finance unveils new tools to boost SME global trade

27 June 2025
Suspect charged with murder of two Israeli embassy employees in Washington

Suspect charged with murder of two Israeli embassy employees in Washington

7 June 2025
All we know about Richard Osman’s Thursday Murder Club Netflix trailer drops

All we know about Richard Osman’s Thursday Murder Club Netflix trailer drops

29 May 2025
Unemployment in EU going down among all age groups except young people

Unemployment in EU going down among all age groups except young people

6 June 2025
European Press

European-press.com shares the latest news from Europe and around the world. It covers topics such as business, technology, sports, health, entertainment, and lifestyle. Feel free to get in touch with us!

Disclaimer  Privacy Policy – EU  Imprint 

Contact Us

What’s New Here!

  • At least one dead after Russia launches strikes on Odesa and Kharkiv
  • Naz Reid lands massive $125M Timberwolves contract extension
  • Anna Wintour ruined her Vogue legacy in one crucial way
  • Maxwell Lewis becomes Nets roster casualty

Subscribe to Our Newsletter

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Translate »
European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
×